HomeATAI • NASDAQ
add
Atai Beckley NV
$4.32
Makalipas ang Oras ng Trabaho:(0.93%)-0.040
$4.28
Sarado: Dis 5, 6:25:25 PM GMT-5 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$4.40
Sakop ng araw
$4.22 - $4.46
Sakop ng taon
$1.15 - $6.73
Market cap
1.57B USD
Average na Volume
4.78M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 749.00K | 1,772.50% |
Gastos sa pagpapatakbo | 14.50M | 41.31% |
Net na kita | -61.07M | -132.34% |
Net profit margin | -8.15K | 87.59% |
Kita sa bawat share | -0.28 | -75.00% |
EBITDA | -28.20M | -25.24% |
Aktuwal na % ng binabayarang buwis | -0.17% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 114.61M | 33.39% |
Kabuuang asset | 239.82M | 21.42% |
Kabuuang sagutin | 79.91M | 56.07% |
Kabuuang equity | 159.91M | — |
Natitirang share | 363.19M | — |
Presyo para makapag-book | 6.67 | — |
Return on assets | -33.14% | — |
Return on capital | -44.29% | — |
Cash Flow
Net change in cash
| (USD) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -61.07M | -132.34% |
Cash mula sa mga operasyon | -23.26M | -20.27% |
Cash mula sa pag-invest | -67.55M | -371.95% |
Cash mula sa financing | 59.74M | 1,120.76% |
Net change in cash | -31.54M | -396.69% |
Malayang cash flow | -29.15M | -248.15% |
Tungkol
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Itinatag
2018
Website
Mga Empleyado
54
